Markets:

Overview

News

Currencies

International

Treasuries

Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

0.7899 -3.5701 (-81.88%)

Streaming Delayed Price Updated: 12:02 PM EST, Dec 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Vistagen Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Why Did Vistagen Stock Tank 82% Today? ↗

Today 10:53 EST

Via Stocktwits

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 17, 2025

Via Benzinga

Vistagen (VTGN) Q2 2026 Earnings Call Transcript ↗

November 14, 2025

Vistagen (VTGN) Q2 2026 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Earnings Scheduled For November 13, 2025 ↗

November 13, 2025

Via Benzinga

Examining the Future: VistaGen Therapeutics's Earnings Outlook ↗

November 12, 2025

Via Benzinga

Vistagen (VTGN) Q1 R&D Expense Jumps 54% ↗

August 07, 2025

Via The Motley Fool

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Insights into VistaGen Therapeutics's Upcoming Earnings ↗

June 16, 2025

Via Benzinga

Earnings Scheduled For February 13, 2025 ↗

February 13, 2025

Via Benzinga

Recap: Vistagen Therapeutics Q3 Earnings ↗

February 13, 2024

Via Benzinga

Insights Ahead: VistaGen Therapeutics's Quarterly Earnings ↗

August 06, 2025

Via Benzinga

Earnings Scheduled For June 17, 2025 ↗

June 17, 2025

Via Benzinga

VTGN Stock Earnings: VistaGen Therapeutics Beats EPS, Misses Revenue for Q1 2025 ↗

August 13, 2024

VTGN stock results show that VistaGen Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2025.

Via InvestorPlace

3 Stocks Under $15 That Could Make You a Millionaire ↗

July 26, 2024

Investors looking for millionaire status in the coming years should consider three stocks under $15 that could be worth buying.

Via InvestorPlace

VTGN Stock Earnings: VistaGen Therapeutics Beats EPS, Misses Revenue for Q4 2024 ↗

June 12, 2024

VTGN stock results show that VistaGen Therapeutics beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2024.

Via InvestorPlace

3 Must-Have Penny Stocks to Boost Your 2024 Portfolio ↗

May 14, 2024

Though volatility remains high, these penny stocks promise significant returns, especially in this high-interest rate economic climate.

Via InvestorPlace

VistaGen Therapeutics's Earnings: A Preview ↗

February 12, 2024

Via Benzinga

Meme Stock Rebound: 3 Reddit Favorites Primed for a Resurgence ↗

May 13, 2024

The internet and forums such as Reddit, are rife with misinformation about stock prospects. However, these three might have potential.

Via InvestorPlace

7 Stocks Under $15 Predicted to Boom in the Next 2 Years ↗

April 19, 2024

Discover seven promising stocks priced under $15, leading in sectors like financial services, biotechnology, and energy.

Via InvestorPlace

Millionaire Makers: 3 Stocks Under $10 Set to Skyrocket by 2027 ↗

April 09, 2024

Explore three stocks under $10 in electronic equipment and instruments, technology hardware, storage and peripherals, and biotechnology.

Via InvestorPlace

Secret Superstars: 3 Unknown Stocks to Turn $5K into $100K by 2027 ↗

March 31, 2024

Learn the potency of lesser-known stocks and explore their fundamental edge in technology distribution, food retail, and biotechnology.

Via InvestorPlace

10 Health Care Stocks Whale Activity In Today's Session ↗

February 19, 2024

Via Benzinga

3 Revolutionary Biotech Stocks Poised for 10X Surge ↗

February 19, 2024

Discover three biotech stocks set to soar in a $3.08 trillion market, merging medical innovations with financial growth opportunities.

Via InvestorPlace

3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave ↗

February 14, 2024

Explore hidden-gem biotech stocks set for growth in a booming market. Uncover top picks ready to redefine healthcare innovation.

Via InvestorPlace

3 Penny Stocks to Buy for the Next Bull Run: February 2024 ↗

February 07, 2024

As the market pivots in 2024, dive into the dynamic world of penny stocks, revealing the top choices for February's exhilarating bull run.

Via InvestorPlace

3 Penny Stocks to Turn $999 Into $1 Million: January 2024 ↗

January 26, 2024

With our strengthening economy, you need to invest in penny stocks that will deliver high future returns, these three are your best bets.

Via InvestorPlace

Topics Economy

Undervalued VistaGen Therapeutics, Analyst Highlights Potential In Anxiety Treatment ↗

December 04, 2023

William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for social anxiety...

Via Benzinga

Anxiety-Focused Stock Vistagen Therapeutics Is An Undervalued Late-Stage Neurology Player: Analyst ↗

November 14, 2023

Analysts at Stifel recently initiated coverage on Vistagen Therapeutics Inc (NASDAQ: VTGN), emphasizing the potential of its lead asset, fasedienol, in clinical development for social anxiety disorder...

Via Benzinga

Earnings Scheduled For February 13, 2024 ↗

February 13, 2024

Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million.

Via Benzinga

Earnings Scheduled For November 9, 2023 ↗

November 09, 2023

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million.

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

Headline News about Vistagen Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today